TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1599352

Group type: EXPERIMENTAL
Intervention: Single-dose therapy with norfloxacin (800 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 3-day therapy with norfloxacin (400 mg twice daily)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 156
Study: 6327800

Group type: COMPARATOR
Intervention: Sodium valproate (200 or 400 mg oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium valproate (600-1000 mg/day, long-term administration)
Number of subjects: 20
Study: 31492603

Group type: EXPERIMENTAL
Intervention: Succinylated gelatin infusion (10 ml/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ringer's lactate infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Succinylated gelatin infusion
Number of subjects: 0
Study: 29557399

Group type: EXPERIMENTAL
Intervention: 4.0 mm long implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10.0 mm long implants
Number of subjects: 80
Study: 27144672

Group type: EXPERIMENTAL
Intervention: Post-operative RT with TST/NMES therapy (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Post-operative RT alone (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (non-radiated muscle)
Number of subjects: 30
Study: 25035200

Group type: EXPERIMENTAL
Intervention: Structured voice rehabilitation with a speech-language pathologist
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no voice rehabilitation)
Number of subjects: 69
Study: 23234816

Group type: EXPERIMENTAL
Intervention: Chlorella group (C. vulgaris extract 1200 mg/day + metformin 750 mg/day + vitamin E 200 mg/day for 3 months)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Metformin group (metformin 1250 mg/day + vitamin E 200 mg/day for 3 months)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Chlorella group
Number of subjects: 76
Study: 20879960

Group type: EXPERIMENTAL
Intervention: Matsuda Index for NFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Matsuda Index for IFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Matsuda Index for diabetes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disposition Index for NFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disposition Index for IFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disposition Index for diabetes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Matsuda Index differences between tests for NFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Matsuda Index differences between tests for IFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Matsuda Index differences between tests for diabetes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disposition Index differences between tests for NFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disposition Index differences between tests for IFG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disposition Index differences between tests for diabetes
Number of subjects: 78
Study: 18813732

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15659542

Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg every 24 h intravenously for 7-14 days)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Comparator (vancomycin or semi-synthetic penicillins for 7-14 days)
Number of subjects: 133
Study: 12030667

Group type: COMPARATOR
Intervention: Group-based parenting programmes
Number of subjects: 23
Study: 10342225

Group type: EXPERIMENTAL
Intervention: Fermented milk product containing 10(7) cfu/ml L. johnsonii La1 (group B)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fermented milk product containing 10(6) cfu/ml L. johnsonii La1 (group C)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fermented milk product fermented by Streptococcus thermophilus (group A)
Number of subjects: 3
Study: 7875642

Group type: EXPERIMENTAL
Intervention: Nefazodone (50, 100, and 200 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydroxy‐nefazodone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nefazodone and Hydroxy‐nefazodone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 32
Study: 3409855

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented milk formula (NMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk formula (MF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 0
Study: 31571270

Group type: EXPERIMENTAL
Intervention: 30‐μs pulse width settings
Number of subjects: 16

Group type: COMPARATOR
Intervention: 60‐μs pulse width settings
Number of subjects: 16
Study: 29307527

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy followed by management as usual
Number of subjects: 684

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 684
Study: 28856511

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 80
Study: 23596055

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin and paclitaxel with radiation
Number of subjects: 70

Group type: COMPARATOR
Intervention: High-dose cisplatin and radiation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy and radiation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Induction chemotherapy followed by high-dose cisplatin and radiation
Number of subjects: 70
Study: 22840826

Group type: EXPERIMENTAL
Intervention: Peer mentoring program
Number of subjects: 158
Study: 20386919

Group type: EXPERIMENTAL
Intervention: Upright posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 65 degrees R posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 degrees R posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supine posture
Number of subjects: 10
Study: 19102907

Group type: EXPERIMENTAL
Intervention: CABG + stem cell transplantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 20
Study: 15911548

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (3 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (7 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fosfomycin (single dose)
Number of subjects: 62
Study: 12644731

Group type: EXPERIMENTAL
Intervention: Acamprosate therapy
Number of subjects: 814

Group type: COMPARATOR
Intervention: Standard cohort (no pharmacotherapy)
Number of subjects: 814
Study: 10596714

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (300 mg b.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous ceftazidime (1 g i.v. t.d.)
Number of subjects: 35
Study: 8976627

Group type: EXPERIMENTAL
Intervention: Modified composite strength (MCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard strength data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isometric strength measure
Number of subjects: 0
Study: 1610994

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 19
Study: 6742528

Group type: EXPERIMENTAL
Intervention: Immunotherapy with a commercial standardized aluminum hydroxide‐bound dog dander extract (15 subjects)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo injections containing histamine (12 subjects)
Number of subjects: 27
Study: 31831074

Group type: EXPERIMENTAL
Intervention: Biopsychosocial multidisciplinary intervention (physiotherapy, cognitive-behavioral therapy, medication)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Biopsychosocial multidisciplinary intervention
Number of subjects: 501
Study: 26954373

Group type: EXPERIMENTAL
Intervention: High social acceptance (parent- and adolescent-rated)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low social acceptance (parent- and adolescent-rated)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Social acceptance
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Inattention
Number of subjects: 93
Study: 26833250

Group type: EXPERIMENTAL
Intervention: Intervention units (team-based interprofessional care)
Number of subjects: 1384
Study: 25561122

Group type: COMPARATOR
Intervention: Oat bran shake (OB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Flaxseed shake (F)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unripe banana flour shake (UB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: White bean extract shake (WB)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Control shake (C)
Number of subjects: 22
Study: 22828460

Group type: EXPERIMENTAL
Intervention: Astaxanthin (Asx)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 32
Study: 21060068

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 4162
Study: 17626140

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 plus electrolytes (PEG+E)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16302897

Group type: EXPERIMENTAL
Intervention: Biventricular pacing system (n = 103)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Right ventricular pacing system (n = 81)
Number of subjects: 184
Study: 12479191

Group type: EXPERIMENTAL
Intervention: Esmolol 1.0 mg x kg(‐1) and Nicardipine 30 microg x kg(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study: 9452149

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group 1 (DLCO increased by +23%)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Group 2 (DLCO decreased by -17.5%)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Group 1 vs Group 2
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of DLCO changes
Number of subjects: 32
Study: 8545860

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1‐2 mg/kg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 2 gm/day (MMF2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 3 gm/day (MMF3)
Number of subjects: 47
Study: 2040324

Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 67

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study: 7471966

Group type: EXPERIMENTAL
Intervention: Factor XIII level measurement before and after surgery
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentration measurement before and after surgery
Number of subjects: 76
Study: 31917386

Group type: EXPERIMENTAL
Intervention: Repeat Hepatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous Radiofrequency Ablation
Number of subjects: 0
Study: 31465859

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise condition of 150 min/week (N = 213)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise condition at 225 min/week (N = 213)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Light intensity stretching-and-toning control condition for 150 min/week (N = 213)
Number of subjects: 639
Study: 28561987

Group type: EXPERIMENTAL
Intervention: Oral misoprostol and Foleys catheter
Number of subjects: 335

Group type: COMPARATOR
Intervention: Oral misoprostol alone
Number of subjects: 335
Study: 25513788

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24773418

Group type: EXPERIMENTAL
Intervention: Television food advertisements
Number of subjects: 284
Study: 22247406

Group type: EXPERIMENTAL
Intervention: Hip flexion assist orthosis
Number of subjects: 62
Study: 20874499

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 195

Group type: COMPARATOR
Intervention: brimonidine 0.2%
Number of subjects: 195
Study: 17426465

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study: 16386089

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 39
Study: 12108888

Group type: EXPERIMENTAL
Intervention: Various treatment modifications including extent of staging work-up, radiation field size and dose, optimal chemotherapy regimen, number of cycles of chemotherapy, limited- vs extended-field radiation therapy and dose.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone in early-stage patients.
Number of subjects: 0
Study: 9796090

Group type: EXPERIMENTAL
Intervention: Low-dose estradiol-releasing vaginal ring
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 84
Study: 7637171

Group type: EXPERIMENTAL
Intervention: Tele-ECG transmission
Number of subjects: 59
Study: 2523663

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Isradipine (various doses)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Isradipine (doses above 10 mg per day)
Number of subjects: 489
Study: 1071960

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of diuretic and propranolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 19
Study: 31208826

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional brackets (CB)
Number of subjects: 88
Study: 31860171

Group type: EXPERIMENTAL
Intervention: PrEP indication
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PrEP indication in trial sites
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-study MSAs
Number of subjects: 105
Study: 29135431

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 19
Study: 25661906

Group type: EXPERIMENTAL
Intervention: aPRP
Number of subjects: 80

Group type: COMPARATOR
Intervention: No aPRP (Control)
Number of subjects: 80
Study: 24029572

Group type: EXPERIMENTAL
Intervention: Dual-chamber laryngeal mask airway (LMA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 300

Group type: COMPARATOR
Intervention: All groups (LMA, tracheal intubation, spinal anesthesia)
Number of subjects: 300
Study: 22261988

Group type: EXPERIMENTAL
Intervention: 4-session preventive group intervention
Number of subjects: 1719

Group type: COMPARATOR
Intervention: 4 sessions providing the same information given in usual care (Control)
Number of subjects: 1719
Study: 19736165

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, thienopyridine, cilostazol)
Number of subjects: 2809
Study: 17762804

Group type: EXPERIMENTAL
Intervention: Back support plus education
Number of subjects: 433

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 433
Study: 15302719

Group type: EXPERIMENTAL
Intervention: Interactive physician seminar
Number of subjects: 637

Group type: COMPARATOR
Intervention: No educational programs (control)
Number of subjects: 637
Study: 11749988

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 34
Study: 9338535

Group type: EXPERIMENTAL
Intervention: CAP System FEIA for egg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CAP System FEIA for milk
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CAP System FEIA for peanut
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CAP System FEIA for fish
Number of subjects: 196

Group type: COMPARATOR
Intervention: Skin prick tests
Number of subjects: 196

Group type: COMPARATOR
Intervention: DBPCFCs
Number of subjects: 196
Study: 7584277

Group type: EXPERIMENTAL
Intervention: Faces with two names (e.g., actors playing nameable characters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental setting testing the frequency effect
Number of subjects: 0
Study: 3425862

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamate (NAAGA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30813625

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) meal
Number of subjects: 46

Group type: COMPARATOR
Intervention: High-fat (HF) meal
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normo-carbohydrate (NC) meal
Number of subjects: 46
Study: 29685815

Group type: EXPERIMENTAL
Intervention: Eculizumab (900 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 34
Study: 26707858

Group type: EXPERIMENTAL
Intervention: Real-time radiation monitoring
Number of subjects: 505

Group type: COMPARATOR
Intervention: No real-time radiation monitoring (Control)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Use of a radioabsorbent drape
Number of subjects: 505

Group type: COMPARATOR
Intervention: No use of a radioabsorbent drape (Control)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) intervention
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Body mass index >30 kg/m2
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Prior MI
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Prior cerebrovascular disease
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Prior coronary artery bypass graft surgery
Number of subjects: 505
Study: 25023799

Group type: EXPERIMENTAL
Intervention: DRC-based diet with 0% WDGS and 84 mg/steer ZH
Number of subjects: 438

Group type: COMPARATOR
Intervention: DRC-based diet with 0% WDGS and no ZH
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: DRC-based diet with 30% WDGS and 84 mg/steer of ZH
Number of subjects: 438

Group type: COMPARATOR
Intervention: DRC-based diet with 30% WDGS and no ZH
Number of subjects: 438
Study: 21925806

Group type: EXPERIMENTAL
Intervention: Varenicline (1mg BID)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 20865877

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 70
Study: 18261965

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg (BMI ≤50 kg/m2) or 60 mg (BMI >50 kg/m2) every 12 hours during hospitalization and once daily for 10 days after discharge
Number of subjects: 223
Study: 16098296

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with abciximab
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 1975
Study: 12112403

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study: 10995136

Group type: EXPERIMENTAL
Intervention: Continuous propofol administration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane 1%
Number of subjects: 50
Study: 7488301

Group type: EXPERIMENTAL
Intervention: Retard capsule containing 20 mg PE hydrochloride and 4 mg CA maleate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aqueous solution of the same active principles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retard capsule under repeated dosing conditions (one capsule b.i.d. during 4 days)
Number of subjects: 20
Study: 2298357

Group type: EXPERIMENTAL
Intervention: Laxative preparation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no laxative preparation)
Number of subjects: 56
Study: 6155029

Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 440 mg total daily dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 10
Study: 31981323

Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 30931663

Group type: EXPERIMENTAL
Intervention: Hi-Fatigue G
Number of subjects: 52

Group type: COMPARATOR
Intervention: Palacos R + G
Number of subjects: 52
Study: 28698347

Group type: EXPERIMENTAL
Intervention: Aortic no-touch OPCABG
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: OPCABG with partial clamp applying carbon dioxide surgical field flooding
Number of subjects: 360

Group type: COMPARATOR
Intervention: OPCABG with partial clamp (control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 360
Study: 25211364

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg⁻¹)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22422304

Group type: COMPARATOR
Intervention: Cholecalciferol 2,000 IU daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5,000 IU daily
Number of subjects: 30
Study: 21542916

Group type: EXPERIMENTAL
Intervention: Insulin treatment as recommended by 4‐T staff
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 4‐T automated insulin dose adjustment algorithm
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Glycaemic target of HbA(1c) ≤6.5%
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Adaptation of trial protocol by staff
Number of subjects: 66
Study: 19762737

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study: 17151589

Group type: EXPERIMENTAL
Intervention: Spread 1 (200 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Spread 2 (400 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control spread (no B-vitamins)
Number of subjects: 150